Search

everythinglearnresearchcommunity

for

Search:↓

Treatments for hair loss vary, but cell-based options may be the future.

The document concludes that PCOS is a complex disorder caused by both genetic and environmental factors, affecting women's health in various ways, and requires personalized treatment.

A substance called DKK-1 increases in balding areas and causes hair cells to die when exposed to DHT.

Lower doses of treatments for hirsutism and acne in PCOS are effective and cause fewer side effects.

Multiple treatments work best for hair loss.

Different types of PCOS have different levels of metabolic problems, with the most severe type showing the highest disturbances.

The document concludes that hair transplantation and gene therapy may be important for future hair loss treatment.

Spironolactone reduces the enzyme activity that converts testosterone to DHT, helping treat excessive hair growth in women.

Testosterone therapy can help improve sexual desire and function in postmenopausal women but may cause side effects and is not FDA-approved for this use.

Hair loss linked to metabolic issues and insulin resistance; early assessment may reduce future health risks.

Amenorrhea is when a woman doesn't have periods, with primary amenorrhea starting by age 15 or within five years of breast development, and secondary amenorrhea when periods stop for three months. It affects 3-4% of women not pregnant, breastfeeding, or in menopause, mainly due to polycystic ovary syndrome, hypothalamic amenorrhea, hyperprolactinemia, and ovarian failure.

With careful management, people with congenital adrenal hyperplasia can have successful pregnancies and become parents.

Finasteride may help some women with hair loss, but better options exist.

Polycystic Ovary Syndrome can cause hair loss and skin issues, and early treatment is important for preventing complications.

PRP injections effectively promote hair growth in androgenetic alopecia patients.

Hormonal therapy is a treatment option for acne, the only medical treatment for hirsutism, and the most promising for androgenetic alopecia.

Amenorrhea, or the absence of periods, should be evaluated by age 15 or within five years of early breast development, and is most commonly caused by conditions like polycystic ovary syndrome and hypothalamic amenorrhea.

Long-term use of dutasteride for enlarged prostate may worsen blood sugar, cholesterol, and erectile dysfunction.

Women with female-pattern baldness produce more testosterone, but 5a-reductase inhibition treatment won't help.

AMH levels can't reliably tell the difference between LOCAH and all types of PCOS in women with excessive hair growth.

The index to ring finger ratio may indicate disease severity in female ankylosing spondylitis patients, but not in males.

Identifying nonclassic congenital adrenal hyperplasia and carriers of CYP21 mutations is challenging, and genetic counseling is recommended due to their prevalence.

The treatment effectively reduced hair growth and was safe for patients with PCOS, but it needs better bleeding control.

Antiandrogens can treat female hormonal conditions, but environmental ones may harm reproductive health.

Women with idiopathic hirsutism and PCOS have higher RBP4 levels, and PCOS is linked to greater insulin resistance; weight management may help both conditions.

Hyperandrogenism increases heart disease risk in premenopausal women, but this risk is linked to obesity in postmenopausal women.

The conclusion is that a more comprehensive and precise approach is needed for diagnosing PCOS to address its broader health risks.

Finasteride and minoxidil are effective for hair loss, but continued research is needed for better treatments.

Finasteride doesn't effectively treat hair loss in postmenopausal women.

Male pattern hair loss is genetic and influenced by hormones, with treatments like minoxidil and surgery available.